Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
BIOR

BIOR - Biora Therapeutics, Inc. Stock Price, Fair Value and News

0.72USD+0.01 (+1.41%)Market Closed

Market Summary

BIOR
USD0.72+0.01
Market Closed
1.41%

BIOR Stock Price

View Fullscreen

BIOR RSI Chart

BIOR Valuation

Market Cap

25.8M

Price/Earnings (Trailing)

-0.23

Price/Sales (Trailing)

84.71

EV/EBITDA

-0.33

Price/Free Cashflow

-0.53

BIOR Price/Sales (Trailing)

BIOR Profitability

EBT Margin

-36434.10%

Return on Equity

110.66%

Return on Assets

-482.22%

Free Cashflow Yield

-189.65%

BIOR Fundamentals

BIOR Revenue

Revenue (TTM)

305.0K

Rev. Growth (Yr)

6.7K%

Rev. Growth (Qtr)

49.72%

BIOR Earnings

Earnings (TTM)

-110.9M

Earnings Growth (Yr)

75.98%

Earnings Growth (Qtr)

72.82%

Breaking Down BIOR Revenue

Last 7 days

-5.3%

Last 30 days

-2.7%

Last 90 days

-35.7%

Trailing 12 Months

-84.7%

How does BIOR drawdown profile look like?

BIOR Financial Health

Current Ratio

0.28

Debt/Equity

-0.19

Debt/Cashflow

-2.61

BIOR Investor Care

Shares Dilution (1Y)

202.59%

Diluted EPS (TTM)

-6.13

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
20230000
20221.2M828.0K726.0K305.0K
2021414.0K666.0K918.0K1.2M
2020113.3M73.3M36.8M162.0K
2019132.0M136.0M140.0M144.0M
2018000128.0M

Tracking the Latest Insider Buys and Sells of Biora Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 05, 2024
howe jill ann
acquired
-
-
12,500
-
Jun 05, 2024
alter jeffrey d.
acquired
-
-
12,500
-
Jun 05, 2024
kotzin brian l.
acquired
-
-
12,500
-
Jun 05, 2024
powell lynne
acquired
-
-
12,500
-
Feb 15, 2024
mohanty aditya p.
acquired
-
-
819,000
chief executive officer
Feb 15, 2024
desparbes eric
acquired
-
-
325,000
chief financial officer
Feb 15, 2024
neumann clarke
acquired
-
-
230,000
see remarks
Sep 18, 2023
athyrium opportunities iii co-invest 1 lp
acquired
-
-
9,235,280
-
Aug 15, 2023
neumann clarke
sold (taxes)
-113,615
3.14
-36,183
see remarks
Aug 15, 2023
neumann clarke
acquired
-
-
210,175
see remarks

1–10 of 50

Which funds bought or sold BIOR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Virtu Financial LLC
reduced
-44.29
-15,000
12,000
-%
May 16, 2024
Athyrium Capital Management, LP
unchanged
-
-2,732,440
12,022,700
16.52%
May 16, 2024
JANE STREET GROUP, LLC
new
-
19,556
19,556
-%
May 15, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
reduced
-28.91
-21,174
29,154
-%
May 15, 2024
Royal Bank of Canada
new
-
-
-
-%
May 15, 2024
STATE STREET CORP
unchanged
-
-8,269
36,380
-%
May 15, 2024
MORGAN STANLEY
added
13.03
-514
5,993
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
sold off
-100
-18.00
-
-%
May 15, 2024
BARCLAYS PLC
unchanged
-
-2,000
6,000
-%
May 15, 2024
Steward Partners Investment Advisory, LLC
unchanged
-
-8.00
35.00
-%

1–10 of 35

Are Funds Buying or Selling BIOR?

Are funds buying BIOR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BIOR
No. of Funds

Unveiling Biora Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 02, 2024
athyrium opportunities 2020 lp
35.4%
13,696,902
SC 13D/A
Feb 14, 2024
armistice capital, llc
3.80%
1,074,895
SC 13G/A
Dec 20, 2023
athyrium opportunities 2020 lp
34.9%
11,351,996
SC 13D/A
Sep 19, 2023
athyrium opportunities 2020 lp
34.0%
8,420,158
SC 13D/A
Mar 13, 2023
athyrium opportunities 2020 lp
16.4%
1,837,286
SC 13D/A
Feb 14, 2023
armistice capital, llc
5.70%
12,989,648
SC 13G
Jan 12, 2023
athyrium opportunities 2020 lp
14.2%
1,457,870
SC 13D/A
Nov 18, 2022
athyrium opportunities 2020 lp
14.6%
36,446,714
SC 13D/A

Recent SEC filings of Biora Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Jun 07, 2024
8-K
Current Report
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
May 31, 2024
EFFECT
EFFECT
May 31, 2024
EFFECT
EFFECT
May 20, 2024
S-3
S-3
May 20, 2024
S-3
S-3
May 15, 2024
10-Q
Quarterly Report

Biora Therapeutics, Inc. News

Latest updates
Defense World20 May 202407:00 am

Biora Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue49.7%542,000362,000182,0002,0008,00014,00080,000104,000107,000435,000182,000463,000167,000106,0008,686,00017,266,00016,828,00020,476,00018,772,00057,230,00047,507,000
Gross Profit-----------627,500182,000463,0002,292,0007,261,50056,000-4,569,000-9,742,000-4,485,000-6,225,00031,117,000-
Operating Expenses20.3%16,058,00013,344,00023,321,00014,936,00015,546,00013,790,00013,967,00014,314,00020,015,00020,594,00030,743,00036,116,00031,631,00016,859,50030,722,00026,483,00042,784,00044,488,00048,616,00045,415,000-
  S&GA Expenses25.3%9,053,0007,226,00012,774,0008,953,0008,356,0008,023,0008,147,0008,410,00013,457,00012,109,00018,517,00022,715,00019,958,000-5,223,0001,563,0001,547,00014,436,00013,378,00015,263,00014,680,000-
  R&D Expenses14.5%7,005,0006,118,00010,547,0005,983,0007,190,0005,767,0005,820,0005,904,0006,558,0008,485,00012,226,00013,401,00011,673,00011,225,00013,043,00012,234,00011,240,00014,609,00017,080,00016,463,000-
EBITDA Margin11.7%-330-373-361-168-132-322-168-179-145-137-145-195---------
Interest Expenses49.8%2,757,0001,840,0002,592,0002,703,0002,680,000-2,773,0002,772,0002,760,0002,186,0003,458,0003,502,0003,520,0002,677,0002,457,0002,489,0002,302,0002,327,0002,321,0002,282,000-
Income Taxes150.5%48,000-95,0001,0004,000-258,500158,000-837,0001,000-122,500--7,000165,000--1,000-37,696,000-712,000---
Earnings Before Taxes73.7%-4,141,000-15,727,000-73,453,000-17,803,000-17,441,000-13,210,000-14,716,000-6,834,000--75,503,500-36,874,000-41,400,000-32,264,000-35,853,500-33,142,000-32,723,000-54,848,000-51,182,000-57,133,000-16,409,000-
EBT Margin10.7%-364-407-399-207-171-361-184-193-156-149-159-214---------
Net Income72.8%-4,189,000-15,413,000-73,454,000-17,807,000-17,441,000-13,722,000-5,114,000-5,513,000-13,808,000-92,874,000-43,744,000-78,531,000-32,263,000-75,528,000-47,065,000-52,783,000-17,152,000-50,476,000-57,133,000-16,409,000-24,019,000
Net Income Margin10.7%-363-406-401-177-137-125-161-188-192-198-250-350---------
Free Cashflow9.4%-12,511,000-13,811,000-11,035,000-11,640,000-12,116,000-11,090,000-9,969,000-19,853,000-24,297,000-40,046,000-43,192,000-36,114,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42018Q4
Assets-26.3%23.0031.0035.0050.0053.0054.0063.0077.0087.0010998.00120129154120186144102116
  Current Assets-26.2%14.0019.0019.0034.0037.0038.0046.0060.0075.0099.0093.0011410112693.00160-75.0089.00
    Cash Equivalents-28.9%11.0015.0013.0026.0030.0030.0037.0049.0067.0088.0054.0066.0065.0092.0059.00113-33.0049.00
  Inventory-------------12.003.0010.0010.00-11.008.00
  Net PPE-1.7%1.001.001.001.001.002.002.002.003.004.005.005.0017.008.0016.0016.00-16.0015.00
  Goodwill0%6.006.006.006.006.006.006.006.006.006.00--6.006.006.006.00-6.006.00
Liabilities-7.1%123133153171158156160173180194275260254261180204195186153
  Current Liabilities-18.8%51.0063.0070.0038.0025.0023.0027.0041.0047.0062.0010386.0080.0073.0087.0095.00-10078.00
  Long Term Debt28.2%19.0015.00-----------------
    LT Debt, Non Current28.2%19.0015.00-----------------
Shareholder's Equity1.2%-100-101---105-102-------------
  Retained Earnings-0.4%-955-950-935-862-844-826-813-808-802-788-695-652-573-541-465-418--348-118
  Additional Paid-In Capital0.6%874869836760758744735731728723538531467453424420-283124
Shares Outstanding9.3%30.0028.0023.0013.0011.009.007.007.007.007.004.003.002.00------
Float----39.00---114---126---96.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Cashflow From Operations9.1%-12,496-13,745-11,054-11,602-12,098-11,018-9,805-19,639-23,955-40,046-43,190-35,686-48,564-70,679-51,863-12,316-30,886-45,845-22,753--
  Share Based Compensation-0.5%1,5391,54610,5312,0142,3842,1662,1391,4462,0532,4023,9353,4592,1661,7962,1632,2282,057592631--
Cashflow From Investing21.7%3,0052,469-1.00-19.00-6.00-72.00-164-214-342211-432-558-463-2,013-1,304-533-1,094-808-1,164--
Cashflow From Financing-63.4%5,10013,918-2,8487,63012,0814,516-1,4771,1253,13473,54031,76737,51522,227103,955-834116,01710,58453,64524,762--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

BIOR Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenues$ 542$ 2
Operating expenses:  
Research and development7,0057,190
Selling, general and administrative9,0538,356
Total operating expenses16,05815,546
Loss from operations(15,516)(15,544)
Interest expense, net(2,757)(2,680)
Gain on warrant liabilities13,915864
Other income (expense), net217(81)
Loss before income taxes(4,141)(17,441)
Income tax expense480
Net loss$ (4,189)$ (17,441)
Net loss per share, basic$ (0.14)$ (1.59)
Net loss per share, diluted$ (0.14)$ (1.59)
Weighted average shares outstanding, basic29,296,76710,970,583
Weighted average shares outstanding, diluted29,296,76710,970,583

BIOR Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash, cash equivalents and restricted cash$ 10,820$ 15,211
Income tax receivable822830
Prepaid expenses and other current assets2,4293,030
Total current assets14,07119,071
Property and equipment, net1,1361,156
Right-of-use assets1,4181,614
Other assets2933,302
Goodwill6,0726,072
Total assets22,99031,215
Current liabilities:  
Accounts payable4,9362,843
Accrued expenses and other current liabilities16,98417,319
Warrant liabilities27,20840,834
Related party senior secured convertible notes, current portion1,9761,976
Total current liabilities51,10462,972
Convertible notes, net of unamortized discount of $103 and $259 as of March 31,2024 and December 31, 2023, respectively4,4979,966
Senior secured convertible notes, net of unamortized discount of $ 13,992 and $11,066 as of March 31, 2024 and December 31, 2023, respectively (Note 6)18,70914,591
Related party senior secured convertible notes net of unamortized discount of $7,058 and $7,951 as of March 31, 2024 and December 31, 2023, respectively (including future interest of $9,747 and $9,747 as of March 31, 2024 and December 31, 2023, respectively) (Note 6)20,07219,179
Derivative liabilities26,21022,899
Other long-term liabilities2,5833,029
Total liabilities123,175132,636
Commitments and contingencies (Note 8)
Stockholders' deficit:  
Common stock - $0.001 par value. 164,000,000 shares authorized;31,166,719 and 28,574,918 shares issued as of March 31, 2024 and December 31, 2023, repectively; 30,429,295 and 27,837,563 shares outstanding as of March 31, 2024 and December 31, 2023, respectively2825
Additional paid-in capital874,013868,591
Accumulated deficit(955,147)(950,958)
Treasury stock - at cost; 737,424 and 737,355 shares as of March 31, 2024 and December 31, 2023, respectively(19,079)(19,079)
Total stockholders' deficit(100,185)(101,421)
Total liabilities and stockholders' deficit$ 22,990$ 31,215
BIOR
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
 CEO
 WEBSITEbioratherapeutics.com
 INDUSTRYBiotechnology
 EMPLOYEES54

Biora Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Biora Therapeutics, Inc.? What does BIOR stand for in stocks?

BIOR is the stock ticker symbol of Biora Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biora Therapeutics, Inc. (BIOR)?

As of Thu Jun 13 2024, market cap of Biora Therapeutics, Inc. is 25.84 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIOR stock?

You can check BIOR's fair value in chart for subscribers.

What is the fair value of BIOR stock?

You can check BIOR's fair value in chart for subscribers. The fair value of Biora Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biora Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIOR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biora Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether BIOR is over valued or under valued. Whether Biora Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Biora Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIOR.

What is Biora Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, BIOR's PE ratio (Price to Earnings) is -0.23 and Price to Sales (PS) ratio is 84.71. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIOR PE ratio will change depending on the future growth rate expectations of investors.